Structural insights into the binding of zoledronic acid with RANKL via computational simulations
Zoledronic acid (ZOL) inhibits receptor activator of nuclear factor-κB ligand (RANKL) and reduces bone turnover. This plays an important role in the development of bisphosphonate-related osteonecrosis of the jaw (BRONJ). Previous reports have shown that ZOL binds to the enzyme farnesyl pyrophosphate...
Main Authors: | Ruijie Wang, Wenjie Zhang, Hailong Ma, Duohong Zou, Zhiyuan Zhang, Shaoyi Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-09-01
|
Series: | Frontiers in Molecular Biosciences |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmolb.2022.992473/full |
Similar Items
-
BISPHOSPHONATE-RELATED OSTEONECROSIS OF THE JAW AND DENTAL IMPLANTS
by: Ala Hassan A. Qamheya, et al.
Published: (2016-01-01) -
Management of a Malpractice Dental Implant Case in a Patient with History of Oral Bisphosphonates Intake: A Case Report and Narrative Review of Recent Findings
by: Massimo Carossa, et al.
Published: (2023-09-01) -
Impact of Bisphosphonate Therapy on Oral Health in Patients with Breast and Prostate Cancer and Bone Metastases: A Comprehensive Study
by: Jacek Calik, et al.
Published: (2024-03-01) -
Bifosfanat kullanımına bağlı çenelerde gelişen osteonekrozlar: Çok merkezli retrospektif çalışma
by: Berkay Tolga Süer, et al.
Published: (2014-08-01) -
Current Controversies on the Pathogenesis of Medication-Related Osteonecrosis of the Jaw
by: Winnie Zee Man Wat
Published: (2016-10-01)